# Efficacy of Fluoxetine Against Seizure-induced Central Apneas

> **NCT02569970** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 70 (actual)

## Conditions studied

- Epilepsy
- Ictal/Post-ictal Hypoxemia

## Interventions

- **DRUG:** fluoxetine 20 mg
- **DRUG:** placebo 20 mg

## Key facts

- **NCT ID:** NCT02569970
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2010-12
- **Final completion:** 2015-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569970, "Efficacy of Fluoxetine Against Seizure-induced Central Apneas". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02569970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*